Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors

Antiviral Therapy

Volumn 15, Issue 3, 2010, Pages 401-412

  Niu, Congrong ^a   Bao, Haiying ^a   Tolstykh, Tatiana ^a   Micolochick Steuer, Holly M ^a   Murakami, Eisuke ^a   Korba, Brent ^b   Furman, Phillip A ^a  

^a PHARMASSET INC   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CLEVUDINE; DEOXYCYTIDINE KINASE; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; THYMIDINE KINASE; THYMIDINE KINASE 1; THYMIDINE KINASE 2; UNCLASSIFIED DRUG; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; GUANINE; NUCLEOSIDE; NUCLEOTIDE; PHOSPHONIC ACID DERIVATIVE; PYRIMIDINONE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE; URACIL ARABINOSIDE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; EVALUATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INCIDENCE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS INHIBITION; ANALOGS AND DERIVATIVES; CELL CULTURE; CELL LINE; DRUG COMBINATION; DRUG EFFECTS; LIVER CELL; MICROBIAL SENSITIVITY TEST; VIROLOGY;

ADENINE; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; CELL LINE; CELLS, CULTURED; DRUG ANTAGONISM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; NUCLEOSIDES; NUCLEOTIDES; ORGANOPHOSPHONATES; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; THYMIDINE;

EID: 77952892979     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1541     Document Type: Article

References (31)

1. Lok AS. Hepatitis B infection: pathogenesis and management. J Hepatol 2000; 32:89-97.
2. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28:112-125. (Pubitemid 44289094)
3. Korba BE, Furman PA, Otto MJ. Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Rev Anti Infect Ther 2006; 4:549-561. (Pubitemid 44523935)
4. Seigneres B, Martin P, Werle B, et al. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 2003; 47:1842-1852. (Pubitemid 36637804)
5. Peek SF, Cote PJ, Jacob JR, et al. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-β, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 2001; 33:254-266.
6. Marcellin P, Mommeja-Marin H, Sacks SL, et al. A Phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004; 40:140-148.
7. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007; 45:1172-1178.
8. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007; 46:1041-1048.
9. Murakami E, Bao H, Basavapathruni A, et al. Mechanism of action of (-)-(2r,4r)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl) thymine as an anti-HIV agent. Antivir Chem Chemother 2007; 18:83-92. (Pubitemid 46808495)
10. Murakami E, Bao H, Ramesh M, et al. Mechanism of activation of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine and inhibition of hepatitis C virus NS5b RNA polymerase. Antimicrob Agents Chemother 2007; 51:503-509. (Pubitemid 46185267)
11. Hassan AE, Pai BS, Lostia S, et al. Synthesis and antiviral evaluation of 2′,3′-dideoxy-2′-fluoro-3′- C-hydroxymethyl-beta-D- arabinofuranosyl pyrimidine nucleosides. Nucleosides Nucleotides Nucleic Acids 2003; 22:891-894. (Pubitemid 37139283)
12. Stuyver LJ, Lostia S, Adams M, et al. Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′- didehydrocytidine analogues. Antimicrob Agents Chemother 2002; 46:3854-3860. (Pubitemid 35403261)
13. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
14. Zhu QY, Scarborough A, Polsky B, Chou TC. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. AIDS Res Hum Retroviruses 1996; 12:507-517. (Pubitemid 26104468)
15. Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997; 41:1231-1236. (Pubitemid 27231419)
16. Ho HT, Hitchcock MJ. Cellular pharmacology of 2′,3′-dideoxy- 2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother 1989; 33:844-849. (Pubitemid 19146572)
17. Franzolin E, Rampazzo C, Perez-Perez MJ, Hernandez AI, Balzarini J, Bianchi V. Bromovinyl-deoxyuridine: a selective substrate for mitochondrial thymidine kinase in cell extracts. Biochem Biophys Res Commun 2006; 344:30-36.
18. Rampazzo C, Fabris S, Franzolin E, Crovatto K, Frangini M, Bianchi V. Mitochondrial thymidine kinase and the enzymatic network regulating thymidine triphosphate pools in cultured human cells. J Biol Chem 2007; 282:34758-34769. (Pubitemid 350232408)
19. Ganem D, Schneider R. Hepadnaviridae: the viruses and their replication. In Knipe D, Howley P (Editors). Field's Virology. Philadelphia: Lippincott-Raven 2001; pp. 2923-2970.
20. Lee JY, Locarnini S. Hepatitis B virus: pathogenesis, viral intermediates, and viral replication. Clin Liver Dis 2004; 8:301-320. (Pubitemid 38748606)
21. Colledge D, Civitico G, Locarnini S, Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000; 44:551-560.
22. Korba BE. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res 1996; 29:49-51.
23. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26:216-225. (Pubitemid 27280328)
24. Chin R, Shaw T, Torresi J, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001; 45:2495-2501.
25. Fu L, Liu SH, Cheng YC. Sensitivity of L-(-)-2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem Pharmacol 1999; 57:1351-1359. (Pubitemid 29225097)
26. Ono SK, Kato N, Shiratori Y, et al. The polymerase I528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107:449-455. (Pubitemid 32167991)
27. Liu SH, Grove KL, Cheng YC. Unique metabolism of a novel antiviral l-nucleoside analog, 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother 1998; 42:833-839.
28. Ferraro P, Nicolosi L, Bernardi P, Reichard P, Bianchi V. Mitochondrial deoxynucleotide pool sizes in mouse liver and evidence for a transport mechanism for thymidine monophosphate. Proc Natl Acad Sci U S A 2006; 103:18586-18591. (Pubitemid 44913454)
29. Xu Y, Johansson M, Karlsson A. Human UMP-CMP kinase 2, a novel nucleoside monophosphate kinase localized in mitochondria. J Biol Chem 2008; 283:1563-1571.
30. Chen YL, Lin DW, Chang ZF. Identification of a putative human mitochondrial thymidine monophosphate kinase associated with monocytic/macrophage terminal differentiation. Genes Cells 2008; 13:679-689.
31. Niu C, Murakami E, Furman PA. Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes. Antivir Ther 2008; 13:263-269. (Pubitemid 351535377)